PRTA Prothena Corp Public Ltd Co

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRTA

Price (delayed)

$34.89

Market cap

$1.87B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.35

Enterprise value

$1.21B

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating ...

Highlights
Prothena's revenue has soared by 145% from the previous quarter
The company's gross profit has surged by 145% QoQ
Prothena's debt has increased by 34% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.prothena.com/
Peers: ALKS AMRN ALNY

Key stats

What are the main financial stats of PRTA
Market
Shares outstanding
53.67M
Market cap
$1.87B
Enterprise value
$1.21B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.03
Price to sales (P/S)
13.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.59
Earnings
Revenue
$140.98M
EBIT
-$86.52M
EBITDA
-$78.92M
Free cash flow
-$89.26M
Per share
EPS
-$1.35
Free cash flow per share
-$1.67
Book value per share
$11.53
Revenue per share
$2.63
TBVPS
$13.95
Balance sheet
Total assets
$746.92M
Total liabilities
$129.69M
Debt
$10.74M
Equity
$617.23M
Working capital
$637.23M
Liquidity
Debt to equity
0.02
Current ratio
12.94
Quick ratio
12.69
Net debt/EBITDA
8.38
Margins
EBITDA margin
-56%
Gross margin
100%
Net margin
-51.9%
Operating margin
-79.9%
Efficiency
Return on assets
-9.9%
Return on equity
-12.1%
Return on invested capital
-876.9%
Return on capital employed
-12.5%
Return on sales
-61.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRTA stock price

How has the Prothena stock price performed over time
Intraday
7.09%
1 week
5.12%
1 month
-4.88%
1 year
-42.7%
YTD
-42.09%
QTD
-27.69%

Financial performance

How have Prothena's revenue and profit performed over time
Revenue
$140.98M
Gross profit
$140.98M
Operating income
-$112.59M
Net income
-$73.2M
Gross margin
100%
Net margin
-51.9%
Prothena's revenue has soared by 145% from the previous quarter
The company's gross profit has surged by 145% QoQ
Prothena's net margin has soared by 98% YoY and by 79% from the previous quarter
The operating margin has soared by 97% year-on-year and by 73% since the previous quarter

Growth

What is Prothena's growth rate over time

Valuation

What is Prothena stock price valuation
P/E
N/A
P/B
3.03
P/S
13.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.59
The company's EPS has surged by 61% YoY and by 51% QoQ
The company's equity has surged by 53% YoY and by 6% QoQ
PRTA's price to book (P/B) is 37% lower than its last 4 quarters average of 4.8 and 16% lower than its 5-year quarterly average of 3.6
Prothena's revenue has soared by 145% from the previous quarter
PRTA's price to sales (P/S) is 96% lower than its 5-year quarterly average of 341.1 and 71% lower than its last 4 quarters average of 45.1

Efficiency

How efficient is Prothena business performance
The company's return on sales has surged by 98% YoY and by 77% QoQ
The ROE has soared by 67% YoY and by 52% from the previous quarter
The ROIC has soared by 66% from the previous quarter and by 34% YoY
Prothena's return on assets has surged by 64% YoY and by 51% QoQ

Dividends

What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTA.

Financial health

How did Prothena financials performed over time
PRTA's current ratio is up by 37% since the previous quarter and by 25% year-on-year
The quick ratio has increased by 37% since the previous quarter and by 29% year-on-year
Prothena's debt is 98% less than its equity
Prothena's debt to equity has surged by 100% QoQ
The company's equity has surged by 53% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.